FindTrial
Sign In

To assess the cyclophilin A levels in diabetic patients with or without vascular disease.

Cyclophilin A as a predictor of vascular risk in patients with type II diabetes Mellitus (T2DM) â?? A prospective observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2014/12/005329
Enrollment
1000
Registered
2014-12-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with T2DM will take part in this study.

Interventions

None listed

Sponsors

The Madras Medical Mission Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with T2DM will be included

Exclusion criteria

Exclusion criteria: Patients with cardiac diseases other than CAD, non-atherosclerotic vascular disease, inflammatory disease of any cause, other systemic and metabolic diseases, asthma, malignancy, liver disease, kidney disease and pregnant women are excluded from the study.

Design outcomes

Primary

MeasureTime frame
Presence of cyclophilin A levels in diabetic patients.Timepoint: Presence of cyclophilin A levels in diabetic patients.—

Secondary

MeasureTime frame
To test cyclophilin A is a marker of diabetic vascular disease.Timepoint: To test cyclophilin A is a marker of diabetic vascular disease.—

Countries

India

Contacts

Public ContactDrVijayakumar

The Madras Medical Mission Hospital

drkumarvijay@gmail.com044-26565974

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026